VIR - NASDAQ
Vir Biotechnology, Inc.
$8.77
+0.34%Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
At a Glance
Live SnapshotVir Biotechnology, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Steady FCF growth indicates consistent cash generation improvement. On a positive trajectory.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Vir Biotechnology, Inc. Cash Flow Statement
VIR • NASDAQ
| Vir Biotechnology, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||
-438M | -522M | -615.1M | 515.8M | 528.6M | -298.7M | -174.7M | -115.9M | -69.9M | |
21.2M | 14.6M | 19.5M | 6.8M | 5.8M | 5.4M | 4.5M | 2.8M | 432K | |
0.0 | -2.9M | -1.1M | -15.2M | 15.2M | -52K | 14.7M | -480K | -10.9M | |
49.1M | 78.5M | 0.0 | 102.1M | 83.8M | 27.6M | 8.7M | 5.1M | 4.8M | |
-1.6M | 69.5M | 122.5M | 388.4M | -52.6M | 45.2M | 8.9M | 2M | 4.3M | |
(0.0) | (786K) | (0.0) | (252M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-22.4M | -84M | -304.6M | 665.4M | -628.4M | 29.5M | 8.2M | 12.5M | 4.9M | |
-391.8M | -446.4M | -778.8M | 1.7B | -47.6M | -190.9M | -129.6M | -94.1M | -66.4M | |
INVESTING ACTIVITIES | |||||||||
-4.8M | -7.3M | -21.6M | -68M | -21.8M | -6.5M | -8.9M | -8.2M | -2.7M | |
(253K) | (3.4M) | (100K) | (0.0) | (140.8M) | (0.0) | (247.2M) | (25K) | -27.3M | |
-886.3M | -1.2B | -2B | -1.5B | -420.2M | -403.8M | -643.9M | -123.1M | (0.0) | |
1.2B | 1.7B | 2.2B | 351.5M | 301.2M | 400.3M | 396.7M | 72.6M | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | -140.8M | 180K | -247.2M | -1.7M | 0.0 | |
(310.4M) | (499.4M) | (164.7M) | -1.2B | -140.8M | -9.9M | -256.2M | -60.4M | -30M | |
FINANCING ACTIVITIES | |||||||||
4.1M | 4.6M | 7.8M | 28.5M | 85.2M | 529.9M | -3K | 0.0 | 0.0 | |
-361K | -165K | -287K | -260K | -259K | -250K | 4.4M | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -3K | (0.0) | (0.0) | |
0.0 | 0.0 | -100K | 6.6M | 15.4M | -189K | 444.9M | 584K | 0.0 | |
3.8M | 4.4M | 7.4M | 34.8M | 100.3M | 529.5M | 449.2M | 25M | 271.2M | |
CASH FLOW SUMMARY | |||||||||
0.0 | 0.0 | 208K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-77.6M | 57.4M | -606.5M | 504.6M | -88.1M | 328.7M | 63.5M | -129.6M | 174.8M | |
318.7M | 261.3M | 861.3M | 363.4M | 451.5M | 122.8M | 59.4M | 188.9M | 14.1M | |
241.1M | 318.7M | 254.8M | 868M | 363.4M | 451.5M | 122.8M | 59.4M | 188.9M | |
-396.6M | -453.7M | -800.4M | 1.6B | -69.4M | -197.5M | -138.6M | -102.3M | -69.1M |
SEC Filings
VIR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 28, 2026 | May 25, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 16, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 10, 2026 | April 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 04, 2026 | March 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 02, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 25, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 19, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 23, 2026 | December 31, 2025 | 2025 |
Related Guides
Continue your VIR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.